The Latest Cardiac and Vascular News
Company Received Final Positive Reimbursement Decision for VAZKEPA® by UK’s NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Initiated Comprehensive Cost Reduction Plan in June to Address Market Dynamics in the U.S. with Expected Savings of $100 Million Over 12 Months* […]
— Newly published final guidance by the National Institute for Health and Care Excellence (NICE) in the UK confirms its prior draft recommendation for the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk who […]
UK’s NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk who have elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]) and established cardiovascular disease (eCVD) 1,2 Positive […]
— Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in European Launches and Global Expansion — — Reduces U.S. Commercial Organization by Ninety Percent of Pre-Pandemic / Pre-Generic Competition Levels — — Creates Core Focused U.S. Commercial Team to […]
— Experienced Executive Brings More Than Twenty Years of Global Financial Leadership to Amarin — — Michael W. Kalb to Depart Amarin to Pursue Other Interests — DUBLIN, Ireland and BRIDGEWATER, N.J., June 06, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Tom Reilly as […]
Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company’s Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board’s Commitment to Ongoing Refreshment and […]
Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Continued Progress on Go-To-Market Strategy in the US Plans for Regulatory Filings for Approval of VASCEPA® (icosapent ethyl) in Several Additional Countries in 2022 Company to […]
The latest prespecified and post hoc sub-analysis of the landmark REDUCE-IT® study, published today in the Journal of the American College of Cardiology (JACC), demonstrated that VASCEPA® (icosapent ethyl) significantly reduces the total ischemic event risk of cardiovascular death, stroke, myocardial infarction (heart attack), coronary revascularization, or hospitalization for unstable angina by 35% […]
Experimental trial research presented at the American College of Cardiology’s 71st Annual Scientific Session showed that the combinations of EPA/atorvastatin active metabolite (ATM) and of EPA/rosuvastatin (rosuva) reduced lipid oxidation by 86% and 75%, respectively (p<0.001) DUBLIN, Ireland and BRIDGEWATER, N.J., April 01, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc […]
Marks First Health Technology Assessment (HTA) Reimbursement in Europe and Initiation of Next Phase of the Company’s Growth Strategy Company Provides Progress Update on European and International Expansion Plans DUBLIN, Ireland and BRIDGEWATER, N.J., March 28, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announces that the Company received […]
